US-based pharmaceutical company Genoa Pharmaceuticals has completed a series A venture financing round led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners and participated by three other investors.

The company has raised a total of $62m from the round.

Celgene Corporation’s affiliate Celgene Switzerland, together with a number of family office investors, has provided venture financing to Dragonfly Therapeutics.

Based in the US, Dragonfly is a drug developer that intends to use the proceeds to expedite the development of its natural killer cell-based immunotherapies.

Israeli-based Biomx has completed a series A venture financing round to raise funds required to advance its novel therapeutic pipeline and further enhance its proprietary microbiome modulation platform technologies.

"Celgene Corporation’s affiliate Celgene Switzerland, together with a number of family office investors, has provided venture financing to Dragonfly Therapeutics."

The company develops therapies based on human bacteria and has raised $24m from the round.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Syros Pharmaceuticals has announced its intention to raise funds through issue of 2.5 million shares of its common stock to the public.

Syros is a life sciences company based in the US.

US-based biopharmaceutical company Synlogic has completed a series C preferred stock issue to multiple investors to raise $42m.

The proceeds are intended to be invested for the advancement of the company’s two lead metabolic disease programmes through patient proof-of-concept studies. Part of the funds will also be used to advance the development of earlier product candidates.